ImmunGene is a privately held biotechnology company focused on the development of proprietary antibody-cytokine fusion technology and monoclonal antibody-based therapies to treat cancer, autoimmune disorders, and other diseases. ImmunGene has several programs at various stages of development. ImmunGene is funded by federal government grants including the NIH-SBIR and by private investors including several biotechnology executives.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/07/13 | $9,000,000 | Series A |
Ally Bridge Group | undisclosed |
